Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06736626 · ClinicalTrials.gov registry record
The xDAPT External Validation Study
A clinical trial of Coronary Artery Disease and Percutaneous Coronary Intervention, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 30,000
- Enrollment target
- 1
- Study location
NCT06736626: Completed study of Coronary Artery Disease and Percutaneous Coronary Intervention, sponsored by Icahn School of Medicine at Mount Sinai.
NCT06736626 is a study of Coronary Artery Disease and Percutaneous Coronary Intervention that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 30,000 participants, above the 1,150-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (2509% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06736626, a study of Coronary Artery Disease and Percutaneous Coronary Intervention, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 30,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Dual antiplatelet therapy (DAPT) is routinely recommended after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation to prevent thrombotic complications. However, DAPT is also associated with an increased risk of bleeding, which may have a similar or even greater impact on prognosis compared to recurrent ischemic events. To balance these risks, individualized risk stratification at the time of PCI is crucial for determining the optimal DAPT composition and duration, aiming to reduce thrombotic risk while minimizing bleeding complications. For this purpose, an artificial intelligence-based risk stratification tool (xDAPT, Abbott) was introduced and demonstrated strong clinical performance in its development study (ClinicalTrials.gov identifier: NCT06089304). This analysis aims to evaluate the performance of xDAPT in a real-world cohort of patients who underwent PCI over the past decade at a large urban center (Mount Sinai Hospital, New York).
Primary Outcome
Composite of all-cause death, myocardial infarction, stroke, or stent thrombosis
Conditions Studied
Interventions
- DEVICE Percutaneous coronary intervention
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30,000 participants |
| Start Date | 2012-01-01 |
| Est. Completion | 2024-12-01 |
What the finished NCT06736626 record still lists
NCT06736626 is an observational study that tracks outcomes without assigning an intervention. Its 30,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,150-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (2509% higher).
The record links to 2 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which Percutaneous coronary intervention is the first listed.
NCT06736626 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06736626 about?
NCT06736626 is a clinical study titled "The xDAPT External Validation Study". Dual antiplatelet therapy (DAPT) is routinely recommended after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation to prevent thrombotic complications. However, DAPT is also associated with an increased risk of bleeding, which may have a similar or even greater impac...
What is the current status of trial NCT06736626?
This trial is currently completed. The enrollment target is 30,000 participants. The study started on 2012-01-01. Estimated completion is 2024-12-01.
What conditions does trial NCT06736626 study?
This clinical trial studies the following conditions: Coronary Artery Disease, Percutaneous Coronary Intervention.
What interventions are being tested in trial NCT06736626?
The interventions under investigation include: Percutaneous coronary intervention (DEVICE).
Who is sponsoring clinical trial NCT06736626?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06736626 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06736626's enrollment target sits among peer trials
30,000 1st of 219 the highest of 219 other Coronary Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Factors Affect Outcomes in Cardiovascular Surgery
RECRUITING
-
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health
RECRUITING · NA
-
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00684580 · 30,000 participants
Protocol For Collecting Data On Patients With Childhood Cancer
- NCT03053193 · 30,000 participants
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
- NCT03689595 · 30,000 participants
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
- NCT04834869 · 30,000 participants
COVID-19 Vaccines Safety Tracking (CoVaST)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI